loading page

Development and Validation of a QTc-Prolongation Risk Score to Optimize Interruptive Medication Alerts
  • +2
  • Emily Aboujaoude,
  • Jesni Mathew,
  • Stacey Sobocinski,
  • Mara Villanueva,
  • Chun Feng
Emily Aboujaoude
The University of Texas MD Anderson Cancer Center

Corresponding Author:emilyritaaj@gmail.com

Author Profile
Jesni Mathew
The University of Texas MD Anderson Cancer Center
Author Profile
Stacey Sobocinski
The University of Texas MD Anderson Cancer Center
Author Profile
Mara Villanueva
The University of Texas MD Anderson Cancer Center
Author Profile
Chun Feng
The University of Texas MD Anderson Cancer Center Division of Cancer Medicine
Author Profile

Abstract

Introduction: Drug-drug interaction (DDI) warnings are employed in many institutions when more than one QTc-prolonging medication is prescribed; however, this leads to alert fatigue where alerts are frequently overridden by clinicians due to patient non-specificity or low risk. This study aimed at reducing alert fatigue through developing a custom alert triggered by a patient-specific QTc-prolongation risk score, and validating it against database-driven DDI warnings for QTc prolongation. Methods and Results: Between November 23, 2019 and January 31, 2020, inpatients with a baseline and a follow-up 12-lead ECG reading within 14 days were identified. Each time a QTc-prolonging medication order was signed or verified, the QTc-prolongation risk score was calculated in the electronic health record (EHR), triggering a custom alert in the background. Follow-up 12-lead ECG readings were used to calculate sensitivity and specificity for both the custom alert and the DDI warning. A total of 100 patients had a risk score calculation and were included in our analysis, representing 521 custom alerts and 449 DDI warnings. The preliminary QTc-prolongation risk score did not achieve a reduction in false positive alerts with a cutoff of 10 points. A multiple logistic regression was performed to re-arrange the components and optimize the risk score. Conclusion: Our adjusted QTc-prolongation risk score, with a cutoff of 5 points, achieved a specificity of 66% and a negative predictive value of 83%. These results will allow us to integrate the risk score into the EHR as a guidance tool to predict QTc-prolongation.